Olema Oncology to Participate in Upcoming Investor Conferences in May

Rhea-AI Summary

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will participate in various investor conferences in May, including the BofA Securities Health Care Conference, H.C. Wainwright BioConnect Investor Conference, UBS Spring Biotech Symposium, and TD Cowen Oncology Innovation Summit. The management team will engage in presentations, fireside chats, and one-on-one meetings to discuss the company's targeted therapies for women's cancers.

SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:

BofA Securities Health Care Conference 2024
Date: Tuesday, May 14, 2024, at 4:35 p.m. PT
Location: Encore Hotel in Las Vegas, NV
Format: Presentation

H.C. Wainwright 2^nd Annual BioConnect Investor Conference
Date: Monday, May 20, 2024, at 4:00 p.m. ET
Location: NASDAQ Headquarters in New York, NY
Format: Fireside Chat

UBS Spring Biotech Symposium
Date: Tuesday, May 21, 2024
Location: New York, NY
Format: One-on-one Meetings

TD Cowen 5th Annual Oncology Innovation Summit
Date: Tuesday, May 28, 2024, at 10:00 a.m. ET
Location: Virtual
Format: Fireside Chat

Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days. 

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
ir@olema.com

FAQ

When will Olema Pharmaceuticals participate in the BofA Securities Health Care Conference?

Olema Pharmaceuticals will participate in the BofA Securities Health Care Conference on Tuesday, May 14, 2024, at 4:35 p.m. PT at the Encore Hotel in Las Vegas, NV.

Where can investors access the live webcasts of the presentations?

Investors can access the live webcasts of the presentations and any accompanying materials under the News & Events section of Olema’s investor relations website at ir.olema.com.

What type of format will the H.C. Wainwright 2nd Annual BioConnect Investor Conference feature?

The H.C. Wainwright 2nd Annual BioConnect Investor Conference will feature a Fireside Chat on Monday, May 20, 2024, at 4:00 p.m. ET at the NASDAQ Headquarters in New York, NY.

What is the focus of Olema Pharmaceuticals?

Olema Pharmaceuticals is focused on the discovery, development, and commercialization of targeted therapies for women's cancers.

What is the stock symbol of Olema Pharmaceuticals?

The stock symbol of Olema Pharmaceuticals is OLMA on the Nasdaq.